Treatment for Friedreich’s Ataxia

     A condition called Friedreich’s ataxia is a rare genetic neurological condition, characterized by muscle weakness, loss of sensations, and the loss of control of body movement (ataxia). The central and peripheral nervous systems, heart, and pancreas are affected. Approximately 1 out of 50,000 Caucasians are affected. Initial signs and symptoms typically occur around the second decade of life. Several years after disease onset, the ability to speak may be severely affected. Difficulty swallowing may also occur, however later in the progression of the condition. The abilities to walk, stand, and sit unsupported are generally lost after 10 to 15 years of disease progression.

     There is currently no cure or treatment to halt the progression of Friedreich’s ataxia. Idebenone (Catena) is an antioxidant medication that is structurally related to the antioxidant co-enzyme Q10. Since oxidative stress potentially plays a role in the destruction caused by the condition, the antioxidant may decrease this effect. This medication may work to improve adverse cardiovascular effects of this condition. This medication is not yet approved by the  FDA for use in the U.S. Currently, individuals affected by the condition in the U.S. may be eligible to obtain this medication through a special program currently in place.





Brought to you by Cheek & Scott Drugs, Inc.
A Community Pharmacy serving North Central Florida.

Live Oak:
386-362-2591
1520 Ohio Ave South; Live Oak, FL 32064

Lake City:
386-754-5377
161 Stonegate Ter; Suite 105; Lake City, FL 32024

Online:
www.CheekAndScott.com


Disclaimer